The Thrombectomy Dilemma in Stroke Patients With Active Cancer: To Treat or Not to Treat?
10.5853/jos.2026.00262
- Author:
Yohanna KUSUMA
;
Mikiya BEPPU
;
Beom Joon KIM
;
Sung-Chun TANG
;
Mikito HAYAKAWA
;
Hiroshi YAMAGAMI
;
Hiroyuki KAWANO
;
Teruyuki HIRANO
;
Shinichi YOSHIMURA
;
Hamidon BASRI
;
Richard LI
;
Huy Thang NGUYEN
;
Deidre Anne De SILVA
;
Keun-Sik HONG
;
Jiann-Shing JENG
;
Than G. PHAN
;
Henry MA
;
Bernard YAN
;
- Publication Type:Review
- From:Journal of Stroke
2026;28(2):218-227
- CountryRepublic of Korea
- Language:English
-
Abstract:
Endovascular thrombectomy for acute large-vessel occlusion in patients with active cancer remains a difficult clinical decision. Multiple cohort studies and meta-analyses indicate that, when standard imaging and clinical criteria are applied, reperfusion success is high and symptomatic intracranial hemorrhage is broadly comparable with non-cancer populations, arguing against categorical exclusion. At the same time, registries show lower 90-day functional independence and higher 90-day mortality in active-cancer cohorts—effects likely driven by malignancy-related systemic factors and pre-existing functional compromise rather than procedural harm. This narrative review synthesizes efficacy and safety signals, highlights decision-grade outcomes that are seldom reported—early neurological change, performance status around 90 days, and whether systemic anticancer therapy is started or resumed. It sets out a clinical–ethical–economic framework to support selection, consent, and aftercare, including a pragmatic pathway for under-resourced settings based on non-contrast computed tomography (CT) or single-phase CT angiography where advanced perfusion imaging or magnetic resonance imaging are unavailable. We outline an Asia–Pacific collaborative program designed to identify subgroups that may benefit from reperfusion and initiation of active cancer care.
